<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819581</url>
  </required_header>
  <id_info>
    <org_study_id>SCI-LIDO-PK-005</org_study_id>
    <nct_id>NCT04819581</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects</brief_title>
  <official_title>An Open-label, Randomized, Four-treatment, Four-sequence, Four-period, Crossover, Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scilex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scilex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the systemic exposure and pharmacokinetic parameters of SP-103 topical&#xD;
      system following one, two, or three topical system applications and compare to the&#xD;
      pharmacokinetics of ZTlido.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 3, 2019</start_date>
  <completion_date type="Actual">August 27, 2019</completion_date>
  <primary_completion_date type="Actual">August 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of lidocaine</measure>
    <time_frame>0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose</time_frame>
    <description>Peak plasma concentration of lidocaine after 12 hour topical system application</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Plasma-Concentration Time Curve (AUC) from Time 0 to Time 48 hours</measure>
    <time_frame>0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve from 0 to 48 hours of lidocaine in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Plasma-Concentration Time Curve (AUC) from Time 0 to Time Infinity</measure>
    <time_frame>0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve from 0 to infinite time of lidocaine in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean adhesion score</measure>
    <time_frame>0, 3, 6, 9, 12 hours post-dose</time_frame>
    <description>Adhesion to skin assessed by FDA 0-4 scoring system. The scoring for adhesion of patches is indicated as follows: 0 = ≥ 90% Adhered (essentially no lift off the skin), 1 = ≥ 75% to &lt; 90% Adhered (some edges only lifting off the skin), 2 = ≥ 50% to &lt; 75% Adhered (less than half of the patch lifting off the skin), &gt; 0% to &lt; 50% Adhered but not detached (more than half of the patch lifting off the skin without falling off), and 4 = 0% adhered (patched completely detached). The mean score is calculated as the average of scores at time 3, 6, 9, and 12 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermal response score</measure>
    <time_frame>12.5 and 14 hours post-dose</time_frame>
    <description>Product tolerability is assessed by Dermal Response Score. The application site is evaluated 30 minutes and 2 hours after product removal (12.5 and 14 hours post-dose, respectively). Response score from 0 to 7; 0= No evidence of irritation, 1= Minimal erythema, barely perceptible, 2= Definite erythema, readily visible; minimal edema or minimal papular response, 3= Erythema and papules, 4= Definite edema, 5= Erythema, edema and papules, 6= Vesicular eruption, 7= Strong reaction spreading beyond test (i.e., application) site.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SP-103 (1 topical system)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One topical system applied to the skin on the back for 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP-103 (2 topical systems)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two topical systems applied to the skin on the back for 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP-103 (3 topical systems)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three topical systems applied to the skin on the back for 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZTlido</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three topical systems applied to the skin on the back for 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-103</intervention_name>
    <description>lidocaine topical system 5.4%</description>
    <arm_group_label>SP-103 (1 topical system)</arm_group_label>
    <arm_group_label>SP-103 (2 topical systems)</arm_group_label>
    <arm_group_label>SP-103 (3 topical systems)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZTlido</intervention_name>
    <description>lidocaine topical system 1.8%</description>
    <arm_group_label>ZTlido</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Must be healthy based on by medical history, laboratory work, ECG, and physical exam&#xD;
&#xD;
          -  Body mass index ranging between 18.0-32.5 kg/m2, inclusive&#xD;
&#xD;
          -  If childbearing potential, use of acceptable form of birth control&#xD;
&#xD;
          -  In the case of females of childbearing potential, have a negative serum pregnancy test&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Allergy or known hypersensitivity to lidocaine, amide-type local anesthetics or any&#xD;
             component of the product formulation&#xD;
&#xD;
          -  Any major medical illness 3 months prior or any significant history or ongoing chronic&#xD;
             medical illness affecting the major body systems, including the skin&#xD;
&#xD;
          -  Subjects with conditions that might affect application of the product or its adhesive&#xD;
             properties (including psoriasis, eczema, atopic dermatitis, damaged or irritated&#xD;
             epidermal layer, and excessive hair or oil on the skin)&#xD;
&#xD;
          -  Use of antiarrhymthic drugs (such as tocainide and mexiletine) and local anesthetics&#xD;
             within 14 days prior to product application.&#xD;
&#xD;
          -  History of addiction, abuse, or misuse of any drug&#xD;
&#xD;
          -  Use of nicotine-containing products within 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Boldingh, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AXIS Clinicals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AXIS Clinicals</name>
      <address>
        <city>Dilworth</city>
        <state>Minnesota</state>
        <zip>56529</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

